First Blood-based Biomarker in Response To The Treatment Of The Most Aggressive Prostate Cancer
Now, a study co-led by the Spanish National Cancer Research Center (CNIO) and researchers from Italy and the United Kingdom, and published in European Urology has identified a biomarker that, via liquid biopsy, can determine which of the two treatments would extend the life expectancy of each patient